Leerink Swann Reaffirms “Outperform” Rating for AMAG Pharmaceuticals Inc. (AMAG)
Leerink Swann restated their outperform rating on shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) in a report published on Thursday. The firm currently has a $36.00 price target on the specialty pharmaceutical company’s stock.
Several other research firms have also weighed in on AMAG. Zacks Investment Research upgraded AMAG Pharmaceuticals from a strong sell rating to a hold rating in a report on Tuesday, July 5th. Jefferies Group reduced their target price on AMAG Pharmaceuticals from $58.00 to $45.00 and set a buy rating on the stock in a report on Wednesday, August 10th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. AMAG Pharmaceuticals has a consensus rating of Buy and an average target price of $36.33.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 24.55 on Thursday. The company’s market cap is $838.48 million. AMAG Pharmaceuticals has a 1-year low of $17.92 and a 1-year high of $42.49. The stock’s 50 day moving average price is $24.07 and its 200 day moving average price is $23.98.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.20 by $0.25. AMAG Pharmaceuticals had a positive return on equity of 13.98% and a negative net margin of 4.87%. The business had revenue of $127.40 million for the quarter, compared to analyst estimates of $128.52 million. During the same period last year, the company earned $1.12 EPS. The firm’s revenue was up 46.7% on a year-over-year basis. Equities research analysts forecast that AMAG Pharmaceuticals will post $5.55 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA increased its stake in AMAG Pharmaceuticals by 46.3% in the second quarter. BNP Paribas Arbitrage SA now owns 106,956 shares of the specialty pharmaceutical company’s stock valued at $2,558,000 after buying an additional 33,827 shares in the last quarter. Opaleye Management Inc. increased its stake in AMAG Pharmaceuticals by 46.7% in the first quarter. Opaleye Management Inc. now owns 220,000 shares of the specialty pharmaceutical company’s stock valued at $5,148,000 after buying an additional 70,000 shares in the last quarter. AlphaOne Investment Services LLC increased its stake in AMAG Pharmaceuticals by 5.8% in the first quarter. AlphaOne Investment Services LLC now owns 91,824 shares of the specialty pharmaceutical company’s stock valued at $2,149,000 after buying an additional 5,007 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in AMAG Pharmaceuticals during the first quarter valued at about $236,000. Finally, Goldman Sachs Group Inc. increased its stake in AMAG Pharmaceuticals by 28.7% in the first quarter. Goldman Sachs Group Inc. now owns 278,051 shares of the specialty pharmaceutical company’s stock valued at $6,506,000 after buying an additional 62,061 shares in the last quarter.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.